Spots Global Cancer Trial Database for Phase I Clinical Trial of TQB3915 Tablets in Subjects With Advanced Malignant Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Phase I Clinical Trial of TQB3915 Tablets in Subjects With Advanced Malignant Solid Tumors
Official Title: Phase I Clinical Trial of TQB3915 Tablets in Subjects With Advanced Malignant Solid Tumors
Study ID: NCT05416359
Conditions
Interventions
Study Description
Brief Summary: TQB3915 is a selective estrogen receptor covalent antagonist, by covalently binding to estrogen receptor, by changing the conformation of ERα, blocking intracellular signal transmission, thereby inhibiting the growth of tumor cells.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Sun Yat-Sen University Cancer Canter, Guangzhou, Guangdong, China
Henan Cancer Hospital, Zhengzhou, Henan, China
First Affiliated Hospital with Nanjin Medical University (Jiangsu Province Hospital), Nanjing, Jiangsu, China
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
